Denosumab (Xgeva)
. Draft fact sheet, awaiting Henry's approval. Items marked [check] must be verified before publishing.
← All drugs · Search the portal
Facts
| Topic | Fact | Source (access date) |
|---|---|---|
| First approval | US 1 Jun 2010 (Prolia/Xgeva BLA 125320, Amgen); EU Xgeva 13 Jul 2011; China Xgeva May 2019 (giant cell tumour of bone) | Drugs@FDA via openFDA, https://api.fda.gov/drug/drugsfda.json?search=application_number:BLA125320 (accessed 4 Nov 2026); EMA medicines report, https://www.ema.europa.eu/en/documents/report/medicines-output-medicines-report_en.xlsx (accessed 4 Nov 2026); Amgen China https://amgen.com.cn/en/media/amgen-denosumab.html (4 Nov 2026) |
| Mechanism | Antibody injection that binds RANKL, stopping bone-breaking cells (osteoclasts) from being activated | Amgen China page above |
| Use in osteosarcoma | Trials only; not standard | entries.json (portal export), sources opened 31 Oct to 3 Nov 2026 |
| Combined with | Alone in AOST1321 | entries.json (portal export), sources opened 31 Oct to 3 Nov 2026 |
| Results | COG AOST1321 (NCT02470091), recurrent, ages 11 to 49, 120 mg every 4 weeks: cohort 1 (measurable) 1/15 event-free at 4 months, no responses; cohort 2 (all disease removed) 10/38 event-free at 12 months; targets not met; most common grade 3+ events low calcium 8%, low phosphate 11% | Janeway et al., Clin Cancer Res 2026;32(1):36-44, doi:10.1158/1078-0432.CCR-24-2885 (PMID 41159913) (accessed 4 Nov 2026) |
| Side effects | US Xgeva label: most common tiredness or weakness, low phosphate, nausea; warnings for severe low calcium and jaw osteonecrosis | openFDA label API, https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22XGEVA%22 (accessed 4 Nov 2026) |
| Owner | Amgen; many EU biosimilars authorised (about 29 in EMA list) | EMA medicines report, https://www.ema.europa.eu/en/documents/report/medicines-output-medicines-report_en.xlsx (accessed 4 Nov 2026) |
| Regulatory | US, EU, UK, China: bone metastases, myeloma, giant cell tumour of bone, osteoporosis (Prolia). Not osteosarcoma | entries.json (portal export), sources opened 31 Oct to 3 Nov 2026 |
Hypotheses and open points (not established fact)
- Blocking RANKL slows osteosarcoma: laboratory rationale; not shown in AOST1321.